Absorb III: A Clinical Evaluation of Absorb™ BVS, the Everolimus
Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects
With de Novo Native Coronary Artery Lesions.
Sponsor: Abbott Vascular
PI: Antonis Pratsos, MD
CRC: Lynn Sher - 484.337.4386
ABSORB III will evaluate the safety and effectiveness of the Absorb BVS
System compared to the XIENCE in the treatment of subjects, including
those with diabetes mellitus, with ischemic heart disease caused by up
to two de novo native coronary artery lesions in separate epicardial
SYMPLICITY HTN-4: Renal Denervation in Patients with
Co-PIs: Eric Gnall, MD and Geoff Teehan, MD
CRC: Susan Herring, RN - 484.476.8514
To demonstrate that catheter-based renal denervation is an effective and
safe treatment for uncontrolled hypertension. Subjects with uncontrolled
HTN, SBP >140 and <160 mmHg despite max tolerated doses of 3 or
more anti-hypertensive medications of different classes (one of which
must be a thiazide or thiazide-like diuretic unless documented
intolerance and appropriate renal anatomy.
For additional information on cardiovascular clinical
trials, please call Ann Marie Chikowski, BSN, RN, CCRC, Clinical
Research Manager at 484.476.3030.
For more information, call 1.866.CALL.MLH.